Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
742 participants
INTERVENTIONAL
2007-09-30
2008-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Symbicort pMDI
Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily
Symbicort pMDI
Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily
Symbicort Turbuhaler
Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily
Symbicort Turbuhaler
Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily
Pulmicort Turbuhaler
Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily
Pulmicort Turbuhaler
Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Symbicort Turbuhaler
Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily
Symbicort pMDI
Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily
Pulmicort Turbuhaler
Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Lung function values measured ≥ 50% and ≤ 90% of predicted normal.
* Patients with reversible airway obstruction Daily use of inhaled steroids (any brand) for \>3 months.
Exclusion Criteria
* Respiratory infection affecting the asthma, as judged by the investigator, within 30 days prior to start of randomised treatment.
* Any significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or may influence the results of the study or the patient's ability to participate in the study.
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tomas Andersson
Role: STUDY_DIRECTOR
AstraZeneca
Akos Somoskovi
Role: PRINCIPAL_INVESTIGATOR
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Pleven, , Bulgaria
Research Site
Plovdiv, , Bulgaria
Research Site
Rousse, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Varna, , Bulgaria
Research Site
Benesov U Prahy, , Czechia
Research Site
Hradec Králové, , Czechia
Research Site
Jihlava, , Czechia
Research Site
Kladno, , Czechia
Research Site
Kolín, , Czechia
Research Site
Kutná Hora, , Czechia
Research Site
Litoměřice, , Czechia
Research Site
Neratovice, , Czechia
Research Site
Pardubice, , Czechia
Research Site
Prague, , Czechia
Research Site
Rokycany, , Czechia
Research Site
Strakonice, , Czechia
Research Site
Balassagyarmat, , Hungary
Research Site
Budapest, , Hungary
Research Site
Cegléd, , Hungary
Research Site
Debrecen, , Hungary
Research Site
Deszk, , Hungary
Research Site
Győr, , Hungary
Research Site
Gyula, , Hungary
Research Site
Kaposvár, , Hungary
Research Site
Nyíregyháza, , Hungary
Research Site
Szarvas, , Hungary
Research Site
Százhalombatta, , Hungary
Research Site
Szeged, , Hungary
Research Site
Törökbálint, , Hungary
Research Site
Bialystok, , Poland
Research Site
Bielsko-Biala, , Poland
Research Site
Bydgoszcz, , Poland
Research Site
Chodzież, , Poland
Research Site
Chrzanów, , Poland
Research Site
Karpacz, , Poland
Research Site
Krakow, , Poland
Research Site
Lodz, , Poland
Research Site
Lublin, , Poland
Research Site
Ostrów Wielkopolski, , Poland
Research Site
Poznan, , Poland
Research Site
Skierniewice, , Poland
Research Site
Szczecin, , Poland
Research Site
Tarnów, , Poland
Research Site
Turek, , Poland
Research Site
Wodzisław Śląski, , Poland
Research Site
Wroclaw, , Poland
Research Site
Łomża, , Poland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D5897C00003
Identifier Type: -
Identifier Source: org_study_id